Last reviewed · How we verify
Compounded standard parenteral nutrition
At a glance
| Generic name | Compounded standard parenteral nutrition |
|---|---|
| Also known as | Compounded standard parenteral nutrition (control drug) |
| Sponsor | Fresenius Kabi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial (NA)
- Efficacy and Safety of Numeta G13%E Compared to Compounded Parenteral Nutrition in Preterm Neonates (PHASE3)
- Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS)
- Intensive Nutrition in Critically Ill Adults (PHASE2)
- Complete Shielding of Multivitamins to Reduce Toxic Peroxides in the Parenteral Nutrition: A Pilot Study (NA)
- Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients (PHASE4)
- Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age (PHASE4)
- Early Enteral Nutrition for Severe Acute Pancreatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compounded standard parenteral nutrition CI brief — competitive landscape report
- Compounded standard parenteral nutrition updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI